<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937728</url>
  </required_header>
  <id_info>
    <org_study_id>KMUH-IRB-970119</org_study_id>
    <nct_id>NCT01937728</nct_id>
  </id_info>
  <brief_title>Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)</brief_title>
  <official_title>A Randomized, Multicenter, Open Label Study Evaluating the Efficacy and Safety of Tailored Regimens With Peginterferon Alfa-2a Plus Ribavirin According Viral Kinetics for Genotype 1 Chronic Hepatitis C Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:

        1. To test if 36 weeks of standard dose of ribavirin with PEGASYS® is non-inferior to
           standard dose of 48 weeks of ribavirin with PEGASYS® in SVR for patients with RVR and
           HVL

        2. To test if the 72 weeks of treatment with PEGASYS® plus standard dose ribavirin is
           superior to 48 weeks of the same treatment for patients with HCV RNA seropositivity at
           week 12
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of the present study are:

        1. To evaluate the efficacy and safety of 36-week versus 48-week regimen of PEGASYS®
           (peginterferon alfa-2a, PegIFN) plus standard-dose of ribavirin (RBV) in hepatitis C
           virus (HCV) genotype 1 infected, treatment-naïve CHC patients who have high viral loads
           (HVL, defined as baseline HCV RNA ≧ 400,000 IU/mL) and achieve a rapid virologic
           response (RVR) (defined as seronegativity of HCV RNA at week 4 of treatment)

        2. To evaluate the efficacy and safety of 48-week versus 72-week regimen of PegIFN plus
           standard-dose of RBV in HCV virus genotype 1 infected, treatment-naïve CHC patients with
           PCR-seropositive of HCV RNA at week 12
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>24-week off-treatment period</time_frame>
    <description>Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4 Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>24-week off-treatment period</time_frame>
    <description>adverse event rate and profile</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">542</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>A: Peg-interferon alpha-2a &amp; Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Peg-interferon alpha-2a &amp; Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.
(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Peg-interferon alpha-2a &amp; Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: Peg-interferon alpha-2a &amp; Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm D: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
(Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E: Peg-interferon alpha-2a &amp; Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F: Peg-interferon alpha-2a &amp; Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.
(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A: Peg-interferon alpha-2a &amp; Ribavirin</intervention_name>
    <description>Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA &lt; 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.</description>
    <arm_group_label>A: Peg-interferon alpha-2a &amp; Ribavirin</arm_group_label>
    <other_name>Pegasys &amp; Robatrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B: Peg-interferon alpha-2a &amp; Ribavirin</intervention_name>
    <description>Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.
Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.</description>
    <arm_group_label>B: Peg-interferon alpha-2a &amp; Ribavirin</arm_group_label>
    <other_name>Pegasys &amp; Robatrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C: Peg-interferon alpha-2a &amp; Ribavirin</intervention_name>
    <description>Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.
Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.</description>
    <arm_group_label>C: Peg-interferon alpha-2a &amp; Ribavirin</arm_group_label>
    <other_name>Pegasys, Robatrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D: Peg-interferon alpha-2a &amp; Ribavirin</intervention_name>
    <description>Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.</description>
    <arm_group_label>D: Peg-interferon alpha-2a &amp; Ribavirin</arm_group_label>
    <other_name>PEGASYS, Robatrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E: Peg-interferon alpha-2a &amp; Ribavirin</intervention_name>
    <description>Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.
Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.</description>
    <arm_group_label>E: Peg-interferon alpha-2a &amp; Ribavirin</arm_group_label>
    <other_name>Pegasys, Robatrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F: Peg-interferon alpha-2a &amp; Ribavirin</intervention_name>
    <description>Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.
Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.</description>
    <arm_group_label>F: Peg-interferon alpha-2a &amp; Ribavirin</arm_group_label>
    <other_name>Pegasys, Robatrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients *18 years of age

          -  Patients have never been treated with traditional interferon plus ribavirin or
             peginterferon plus ribavirin

          -  Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test

          -  Detectable serum HCV-RNA and HCV viral genotype 1

          -  Liver biopsy findings consistent with the diagnosis of chronic hepatitis C infection
             with or without compensated cirrhosis (Exception: hemophiliacs in whom biopsy is
             medically contra-indicated do not require biopsy.)

          -  Compensated liver disease (Child-Pugh Grade A clinical classification)

          -  Negative urine or blood pregnancy test (for women of childbearing potential)
             documented within the 24-hour period prior to the first dose of study drug

          -  All fertile males and females receiving ribavirin must be using two forms of effective
             contraception during treatment and during the 6 months after treatment end

        Exclusion Criteria:

          -  Women with ongoing pregnancy or breast feeding

          -  Therapy with any systemic anti-neoplastic or immunomodulatory treatment (including
             supraphysiologic doses of steroids and radiation) *6 months prior to the first dose of
             study drug

          -  Any investigational drug *6 weeks prior to the first dose of study drug

          -  Co-infection with active hepatitis A, hepatitis B and/or human immunodeficiency virus
             (HIV)

          -  History or other evidence of a medical condition associated with chronic liver disease
             other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease,
             alcoholic liver disease, toxin exposures)

          -  Signs or symptoms of hepatocellular carcinoma

          -  History or other evidence of bleeding from esophageal varices or other conditions
             consistent with decompensated liver disease

          -  Neutrophil count &lt;1500 cells/mm3 or platelet count &lt;90,000 cells/mm3 at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia-Yen Dai, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Medical University Chung-Ho Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Chia-Yen Dai</investigator_full_name>
    <investigator_title>Professor, School of Medicine, Hepatology Division</investigator_title>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Genotype 1</keyword>
  <keyword>Peg interferon</keyword>
  <keyword>alfa 1a</keyword>
  <keyword>Ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

